• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Better Therapeutics Inc. (Amendment)

    2/13/24 1:00:29 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTTX alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A MMCAP International Inc. SPC: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

    Better Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    08773T104

    (CUSIP Number)


    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

    Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)


    CUSIP No. 08773T104

     

    Page 2 of 6 Pages


    1

    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     

    MMCAP International Inc. SPC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
              

    (a) ☑
    (b) ☐

     


    3

    SEC USE ONLY

     

              
     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    356,270*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    356,270*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    356,270*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
              

    ☐

     


    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.71%**

    12

    TYPE OF REPORTING PERSON

     

    CO


    FOOTNOTES

    * Consist of 356,270 shares of the Issuer’s common stock.

    ** The percentages used herein are calculated based on 49,861,726 shares of common stock outstanding of the Issuer as reported in the Issuer’s Form S-1 Registration Statement filed with the Securities and Exchange Commission on December 27, 2023.



    CUSIP No. 08773T104

     

    Page 3 of 6 Pages


    1

    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     

    MM Asset Management Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
              

    (a) ☑
    (b) ☐

     


    3

    SEC USE ONLY

     

              
     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    356,270*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    356,270*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    356,270*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
              

    ☐

     


    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.71%**

    12

    TYPE OF REPORTING PERSON

     

    CO


    FOOTNOTES

    * Consist of 356,270 shares of the Issuer’s common stock.

    ** The percentages used herein are calculated based on 49,861,726 shares of common stock outstanding of the Issuer as reported in the Issuer’s Form S-1 Registration Statement filed with the Securities and Exchange Commission on December 27, 2023.



    CUSIP No. 08773T104

     

    Page 4 of 6 Pages

    Item 1 (a). Name of Issuer:

    Better Therapeutics, Inc.

    Item 1 (b). Address of Issuer's Principal Executive Offices:

    548 Market St., #49404, San Francisco, CA, 94101

    Item 2 (a). Name of Person Filing:

    i) MMCAP International Inc. SPC

    ii) MM Asset Management Inc.

    Item 2 (b). Address of Principal Business Office or, if None, Residence:

    i) c/o Mourant Governance Services (Cayman) Limited
    94 Solaris Avenue
    Camana Bay, P.O. Box 1348
    Grand Cayman, KY1-1108, Cayman Islands

    ii) 161 Bay Street
    TD Canada Trust Tower Suite 2240
    Toronto, ON M5J 2S1 Canada

    Item 2 (c). Citizenship:

    i) Cayman Islands
    ii) Ontario, Canada

    Item 2 (d). Title of Class of Securities:

    Common Stock, par value $0.0001

    Item 2 (e). CUSIP Number:

    08773T104

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     (a) ☐ Broker or dealer registered under Section 15 of the Act;

     (b) ☐ Bank as defined in Section 3(a)(6) of the Act;

     (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act;

     (d) ☐ Investment Company registered under Section 8 of the Investment Company Act;

     (e) ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     (f) ☐ Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

     (g) ☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

     (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;


    CUSIP No. 08773T104

     

    Page 5 of 6 Pages

     (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:

     (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

     ☒ If this statement is filed pursuant to Rule 13d-1(c), check this box.

    Item 4. Ownership.

     Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

     (a) Amount beneficially owned: 356,270*

     (b) Percent of class:  0.71%**

     (c) Number of shares as to which such person has:

     (i) Sole power to vote or to direct the vote:  0

     (ii) Shared power to vote or to direct the vote:  356,270*

     (iii) Sole power to dispose or to direct the disposition of:  0

     (iv) Shared power to dispose or to direct the disposition of: 356,270*

    * Consist of 356,270 shares of the Issuer's common stock.

    ** The percentages used herein are calculated based on 49,861,726 shares of common stock outstanding of the Issuer as reported in the Issuer's Form S-1 Registration Statement filed with the Securities and Exchange Commission on December 27, 2023.

    Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

    Item 5. Ownership of Five Percent or Less of a Class.

     If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  X ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     N/A

    Item 8. Identification and Classification of Members of the Group.

     N/A

    Item 9. Notice of Dissolution of Group.

     N/A


    CUSIP No. 08773T104

     

    Page 6 of 6 Pages

    Item 10. Certification.  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    MMCAP International Inc. SPC

     

     

    Date: February 13, 2024

    By: /s/ Ulla Vestergaard                                                      
     

     

          Name: Ulla Vestergaard

          Title: Director

     

     

     

     

     

     

     

     

     

    MM Asset Management Inc.

     

     

    Date: February 13, 2024

    By: /s/ Hillel Meltz                                               
     

     

          Name: Hillel Meltz

          Title: President



    Get the next $BTTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTTX

    DatePrice TargetRatingAnalyst
    11/24/2021$17.00Buy
    Chardan Capital Markets
    11/10/2021Outperform
    Cowen
    More analyst ratings

    $BTTX
    Financials

    Live finance-specific insights

    See more
    • Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape

      3/1/24 9:00:00 AM ET
      $BTCY
      $BTTX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

      Company obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. "We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare providers a clinically proven, convenie

      11/9/23 7:00:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

      Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The

      11/8/23 7:30:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Better Therapeutics Inc. (Amendment)

      SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)

      2/13/24 1:00:29 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Better Therapeutics Inc. (Amendment)

      SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)

      2/12/24 4:28:28 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Better Therapeutics Inc. (Amendment)

      SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)

      1/25/24 4:30:59 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perry David P was granted 839,895 shares, increasing direct ownership by 53% to 2,416,634 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      2/13/24 9:50:33 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perry David P was granted 1,471,453 shares, increasing direct ownership by 1,398% to 1,576,739 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      1/10/24 4:19:25 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perry David P was granted 3,750 shares, increasing direct ownership by 4% to 105,286 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      12/20/23 5:24:37 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BTTX
    Leadership Updates

    Live Leadership Updates

    See more

    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

      Better Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq's continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be d

      3/14/24 9:38:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

      One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

      3/5/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians

      3/4/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

      One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

      3/5/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

      Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022. Gomez-Thinnes brings more than two decades of experience in the healthcare industry, leading the commercialization and launch of products spanning the medical device, prescription medicines and consumer health sect

      10/27/22 7:30:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

      Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t

      6/7/22 7:30:00 AM ET
      $BTTX
      $EXEL
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Chardan Capital Markets initiated coverage on Better Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00

      11/24/21 7:14:30 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on Better Therapeutics

      Cowen initiated coverage of Better Therapeutics with a rating of Outperform

      11/10/21 6:22:09 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:06 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:09 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:08 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care